Interdisziplinäre Empfehlungen zur Behandlung des fortgeschrittenen Nierenzellkarzinoms
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interdisziplinäre Empfehlungen zur Behandlung des fortgeschrittenen Nierenzellkarzinoms
Authors
Keywords
-
Journal
AKTUELLE UROLOGIE
Volume -, Issue -, Pages -
Publisher
Georg Thieme Verlag KG
Online
2020-10-08
DOI
10.1055/a-1252-1780
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
- (2020) Nizar M. Tannir et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
- (2020) Buonerba et al. Cancers
- A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).
- (2020) Marit Ahrens et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.
- (2020) Elizabeth R. Plimack et al. JOURNAL OF CLINICAL ONCOLOGY
- Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?
- (2019) Renate Pichler et al. Cancers
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update
- (2019) Börje Ljungberg et al. EUROPEAN UROLOGY
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2019) Bernard Escudier et al. ANNALS OF ONCOLOGY
- Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.
- (2019) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.
- (2019) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis.
- (2019) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- Empfehlungen zur systemischen Therapie des metastasierten Nierenzellkarzinoms 2019
- (2019) Nils Kröger et al. AKTUELLE UROLOGIE
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
- (2019) Robert J Motzer et al. LANCET ONCOLOGY
- Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study
- (2019) Moshe C Ornstein et al. LANCET ONCOLOGY
- Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
- (2019) Brian I Rini et al. LANCET ONCOLOGY
- The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
- (2019) Brian I. Rini et al. Journal for ImmunoTherapy of Cancer
- The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma
- (2018) Pedro Coelho Barata et al. BRITISH JOURNAL OF CANCER
- Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
- (2018) Toni K. Choueiri et al. EUROPEAN JOURNAL OF CANCER
- Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial
- (2018) Benjamin T. Ristau et al. JOURNAL OF UROLOGY
- Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
- (2018) Arnaud Méjean et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
- (2018) M Gross-Goupil et al. ANNALS OF ONCOLOGY
- Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies
- (2017) Chiara Ciccarese et al. EUROPEAN JOURNAL OF CANCER
- Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025
- (2017) Bernard Escudier et al. EUROPEAN UROLOGY
- Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma
- (2017) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nebenwirkungen der Immun-Checkpoint-Inhibitoren
- (2017) S. Foller et al. UROLOGE
- Nebenwirkungen der Immun-Checkpoint-Inhibitoren
- (2017) S. Foller et al. UROLOGE
- Comparing Everolimus to Sunitinib in Non–clear-cell Renal Cell Carcinoma
- (2016) Axel Bex et al. EUROPEAN UROLOGY
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours
- (2016) Holger Moch et al. EUROPEAN UROLOGY
- Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
- (2016) Alain Ravaud et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression
- (2016) Saby George et al. JAMA Oncology
- RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial
- (2015) J. L. Lee et al. ANNALS OF ONCOLOGY
- Systemic Therapy for Non–clear Cell Renal Cell Carcinomas: A Systematic Review and Meta-analysis
- (2015) Francisco E. Vera-Badillo et al. EUROPEAN UROLOGY
- Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
- (2015) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 2 Trial of Neoadjuvant Axitinib in Patients with Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
- (2014) Jose A. Karam et al. EUROPEAN UROLOGY
- Efficacy of Pre-surgical Axitinib for Shrinkage of Inferior Vena Cava Thrombus in a Patient with Advanced Renal Cell Carcinoma
- (2014) N. Sassa et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib
- (2014) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment Algorithm for Metastatic Renal Cell Carcinoma - Recommendations Based on Evidence and Clinical Practice
- (2014) Lothar Bergmann et al. Oncology Research and Treatment
- Neoadjuvant Sorafenib Treatment of Clear Cell Renal Cell Carcinoma and Release of Circulating Tumor Fragments
- (2014) Gursah Kats-Ugurlu et al. NEOPLASIA
- A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
- (2013) Cora N. Sternberg et al. EUROPEAN JOURNAL OF CANCER
- Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
- (2013) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment selection in metastatic renal cell carcinoma: expert consensus
- (2012) Bernard Escudier et al. Nature Reviews Clinical Oncology
- Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials
- (2010) Axel Bex et al. EUROPEAN UROLOGY
- Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell Carcinoma
- (2010) C. Lance Cowey et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
- (2010) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell Carcinoma
- (2009) Eric Jonasch et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- Surgical Resection of Renal Cell Carcinoma After Targeted Therapy
- (2009) Anil A. Thomas et al. JOURNAL OF UROLOGY
- Can Tyrosine Kinase Inhibitors be Discontinued in Patients with Metastatic Renal Cell Carcinoma and a Complete Response to Treatment? A Multicentre, Retrospective Analysis
- (2008) Manfred Johannsen et al. EUROPEAN UROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search